Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 21;64(10):e00409-20.
doi: 10.1128/AAC.00409-20. Print 2020 Sep 21.

Resistance to Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used Together Is Achieved in Four Steps in Metallo-β-Lactamase-Negative Klebsiella pneumoniae

Affiliations

Resistance to Ceftazidime/Avibactam plus Meropenem/Vaborbactam When Both Are Used Together Is Achieved in Four Steps in Metallo-β-Lactamase-Negative Klebsiella pneumoniae

Punyawee Dulyayangkul et al. Antimicrob Agents Chemother. .

Abstract

Serine β-lactamases are dominant causes of β-lactam resistance in Klebsiella pneumoniae isolates. Recently, this has driven clinical deployment of the β-lactam-β-lactamase inhibitor pairs ceftazidime/avibactam and meropenem/vaborbactam. We show that four steps, i.e., ompK36 and ramR mutation plus carriage of OXA-232 and KPC-3-D178Y variant β-lactamases, confer ceftazidime/avibactam and meropenem/vaborbactam resistance when both pairs are used together. These findings have implications for decision making about sequential and combinatorial use of these β-lactam-β-lactamase inhibitor pairs to treat K. pneumoniae infections.

Keywords: KPC; OXA-48; porin; β-lactamase.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Checkerboard assays for ceftazidime and meropenem in the presence of avibactam and vaborbactam. Each image represents duplicate assays for an 8-by-8 array of wells in a 96-well plate. All wells contained CA-MHB, including avibactam (4 μg · ml−1) and vaborbactam (8 μg · ml−1). A serial dilution of meropenem (MEM; x axis) and ceftazidime (CAZ, y axis) was created from 32 μg · ml−1 in each plate as recorded. All wells were inoculated with a suspension of bacteria, made according to CLSI microtiter MIC guidelines (18), and the plate was incubated at 37°C for 20 h. Growth was recorded by measuring OD600, and growth above background (broth) is shown as a yellow block. Growth at 8 μg · ml−1 ceftazidime and 8 μg · ml−1 meropenem (indicated in red) in the presence of vaborbactam and avibactam defined resistance based on CLSI breakpoints (19). Bacterial suspensions used were as follows: top row, KP21[ramR] ompK36; second row, KP21[ramR] ompK36(pOXA-232); third row, KP21[ramR] M[ompK36](pOXA-232); fourth row, KP21[ramR] M[ompK36] ompK35(pOXA-232); and fifth row, KP47 ompK36(pOXA-232). In each case, bacteria also carried the following plasmids (where tested): first column, pCTX-M-14 P170S; second column, pKPC-3; third column, pKPC-3-D178Y; and fourth column, pKPC-3-V239G.

References

    1. Holt KE, Wertheim H, Zadoks RN, Baker S, Whitehouse CA, Dance D, Jenney A, Connor TR, Hsu LY, Severin J, Brisse S, Cao H, Wilksch J, Gorrie C, Schultz MB, Edwards DJ, Nguyen KV, Nguyen TV, Dao TT, Mensink M, Minh VL, Nhu NT, Schultsz C, Kuntaman K, Newton PN, Moore CE, Strugnell RA, Thomson NR. 2015. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc Natl Acad Sci U S A 112:E3574–E3581. doi:10.1073/pnas.1501049112. - DOI - PMC - PubMed
    1. Cantón R, González-Alba JM, Galán JC. 2012. CTX-M enzymes: origin and diffusion. Front Microbiol 3:110. doi:10.3389/fmicb.2012.00110. - DOI - PMC - PubMed
    1. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, Brolund A, Giske CG. 2009. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 53:3365–3370. doi:10.1128/AAC.00126-09. - DOI - PMC - PubMed
    1. Poirel L, Potron A, Nordmann P. 2012. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 67:1597–1606. doi:10.1093/jac/dks121. - DOI - PubMed
    1. Ehmann DE, Jahić H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A 109:11663–11668. doi:10.1073/pnas.1205073109. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources